
Having an evidence package at launch that satisfies payers’ value criteria will increase the likelihood that payers will reimburse the drug at a desirable price and enable patient access to innovative treatments.

Your AI-Trained Oncology Knowledge Connection!


Having an evidence package at launch that satisfies payers’ value criteria will increase the likelihood that payers will reimburse the drug at a desirable price and enable patient access to innovative treatments.

Published: January 26th 2016 | Updated: